Pharmaco kinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia.

被引：11

作者：

Byrd, John C.

Flinn, Ian W.

Khan, Khuda D.

Kipps, Thomas J.

Aukerman, Lea

Fox, Judith

Girish, Sandhya

Guzy, Serge

Bilic, Sanela

Solinger, Alan

Dort, Sherri

Wang, Yongyu

Hurst, Deborah

O'Brien, Susan

机构：

[1] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA

[2] Johns Hopkins Med Ctr, Baltimore, MD USA

[3] St Francis Canc Res Found, Beech Grove, IN USA

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Novartis Oncol, Florham Pk, NJ USA

[6] XOMA Ltd, Berkeley, CA USA

[7] MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood.V108.11.2837.2837

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2837

引用

页码：803A / 803A

页数：1